ANDA 77716, held by Wockhardt Bio AG. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 77716 (Ondansetron Hydrochloride Preservative Free), held by Wockhardt Bio AG, was first approved by FDA on Dec 26, 2006, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 26, 2006 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron Hydrochloride Preservative FreeEQ 2MG BASE/ML · injectable;injection | Ondansetron Hydrochloride | Rx |
| Apr 19, 2023 | Supplement 6Labeling · Standard review | Approved | None posted |
| Apr 19, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Mar 9, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 14, 2013 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 26, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters